Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04874558 · ClinicalTrials.gov registry record
Ultra-low-dose Chest CT for HHT
A clinical trial of Hereditary Hemorrhagic Telangiectasia, sponsored by Mayo Clinic.
- Active
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT04874558: Active study of Hereditary Hemorrhagic Telangiectasia, sponsored by Mayo Clinic.
NCT04874558 is a study of Hereditary Hemorrhagic Telangiectasia that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 10 participants, below the 1,789-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04874558, a study of Hereditary Hemorrhagic Telangiectasia, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.
Primary Outcome
Number of images detecting PAVM using the ultra-low dose images (50% or lower compared to the full dose)
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Ultra-low dose chest CT
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-04-21 |
| Est. Completion | 2025-12-31 |
What the registry record for NCT04874558 still lists
NCT04874558 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,789-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hereditary Hemorrhagic Telangiectasia appearing as the primary indexed condition, and to 1 intervention - of which Ultra-low dose chest CT is the first listed.
NCT04874558 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04874558 about?
NCT04874558 is a clinical study titled "Ultra-low-dose Chest CT for HHT". This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.
What is the current status of trial NCT04874558?
This trial is currently active not recruiting. The enrollment target is 10 participants. The study started on 2021-04-21. Estimated completion is 2025-12-31.
What conditions does trial NCT04874558 study?
This clinical trial studies the following conditions: Hereditary Hemorrhagic Telangiectasia.
What interventions are being tested in trial NCT04874558?
The interventions under investigation include: Ultra-low dose chest CT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04874558?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04874558 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Hemorrhagic Telangiectasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
RECRUITING
-
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
RECRUITING · Phase 1
-
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
ACTIVE NOT RECRUITING
-
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
ACTIVE NOT RECRUITING · Phase 2
-
Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI